The collaboration, disclosed on October 1, 2024, grants Sun Pharma the worldwide rights to market Fibromun, which is in the final stages of clinical trials for treating soft tissue sarcoma and glioblastoma
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
